Navigation Links
Oral Drug Helps Prevent Clotting After Hip Replacement
Date:6/25/2008

Daily dose of rivaroxaban cut risk of venous thromboembolism, study finds

WEDNESDAY, June 25 (HealthDay News) -- Extended use of the oral drug rivaroxaban helps prevent potentially fatal blood clots after hip replacement surgery, British researchers say.

The risk of venous thromboembolism (VTE) is high after total hip replacement, and the risk can persist after a patient leaves hospital. Current guidelines recommend patients receive a heparin-based preventive drug such as enoxaparin (Lovenox) for a minimum of 10 days, and up to 35 days, after surgery. However, this preventive treatment is not used much after patients leave hospital, according to background information in the study.

The researchers at the London School of Medicine and Dentistry and the Thrombosis Research Institute compared the new oral antithrombotic drug rivaroxaban (Xarelto) with enoxaparin in the treatment of hip replacement patients.

In the randomized, controlled trial, 1,252 patients received 10 milligrams of oral rivaroxaban once daily for 31 to 39 days, followed by placebo injection for 10 to 14 days, while 1,257 patients received 40 milligram once-daily injections of enoxaparin for 10 to 14 days, followed by placebo tablets for 31 to 39 days.

The completed analysis of 864 patients in the rivaroxaban group and 869 patients in the enoxaparin group found that patients in the enoxaparin group were more than four times as likely to suffer deep vein thrombosis, nonfatal pulmonary embolism, or die than patients in the rivaroxaban group -- 9.3 percent versus 2 percent. Both groups had similar rates of bleeding events during treatment.

"Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty [replacement]," the researchers concluded.

The study was released online Wednesday by The Lancet and will be published in an upcoming issue.

"With superior efficacy, no compromise in safety, and a convenient once-daily regimen, rivaroxaban seems an obvious choice for simplified thromboprophylaxis after hip or knee arthroplasty [replacement]," Dr. John Eikelboom and Jeffrey Weitz, of McMaster University in Hamilton, Ontario, Canada, wrote in an accompanying editorial.

More information

The American Academy of Orthopaedic Surgeons has more about total hip replacement.



-- Robert Preidt



SOURCE: The Lancet, news release, June 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Heel Ultrasound Helps Detect Fracture Risk
2. Bat Scan to the Rescue: New Clubhouse CT Scanner Helps Eliminate Exploding Bats
3. Pro Baseball Helps Keep Skin Cancer From Scoring
4. Caregiverlist.com Helps Families Find Quality Senior Care
5. World Renowned Hand Surgeon Helps Patients Conquer Joint Discomfort Naturally
6. Nature Made SAM-e Complete Helps Americans Find Their Good Moods
7. Gene Therapy Helps Dogs Stricken With Cancer
8. New study shows American Cancer Society program helps employers
9. Estrogen therapy helps or hurts the brain depending on reproductive status
10. Online Scheduler Helps Track Kids Shots
11. MassMutual Announces Web Site Enhancement That Helps Employees Save for Retirement Sooner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Greenfield Advisors ... companies in the U.S. for the second year in a row. The Inc. 5000 ... past three years. , “To be on the list once is a great accomplishment, ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second year, ... student to educate the public on the impact of concussions. Brooke Mills, student ... National Concussion Awareness Day. , Brooke is working diligently is to raise awareness ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... of their recently launched community enrichment program. Partnering once again with Boys & ... Superstar competition to help find the area’s very own American Idol. With all ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the ... from around the world, is excited to announce Andrew Ly as the winner of ... pursuits, covering textbook costs. , Ly, who is in his third year at ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
Breaking Medicine Technology: